Navigation Links
Marrow-derived stem cells deliver new cytokine to kill brain tumor cells, offer protection

Attaching a recently discovered cytokine to neural stem cells derived from bone marrow, researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute have developed a tool to track and kill malignant brain tumor cells and provide long-term protection against their return.

Results of an animal study are published in the March 1, 2006 issue of Cancer Research, and the researchers are now applying to regulatory agencies to translate their work into human clinical trials.

Gliomas are highly invasive tumors with poorly defined borders that intermingle with healthy brain tissue, making complete surgical removal nearly impossible. Furthermore, cells separate from the main tumor and migrate to form satellites that escape treatment and often lead to recurrence.

Researchers at the Maxine Dunitz Neurosurgical Institute documented several years ago that some neural stem cells ?"immature" cells that can differentiate into central nervous system cells ?have the ability to target and track glioma cells in the brain, even as they migrate. The researchers identified the mechanism that enables certain neural stem cells to develop this tracking ability and genetically engineered neural stem cells to transport several cytokines ?proteins that regulate immune responses ?to track down and destroy glioma cells.

In 2002, the scientists reported that they had produced central nervous system cells from stem cells derived from bone marrow. Because these stem cells originate in the bone marrow instead of the brain or fetal or embryonic tissue, there is an unlimited supply of cells that are free of ethical and tissue-rejection issues.

This study provides the first documentation that the marrow-derived stem cells possess the same tumor-tracking capability of other neural stem cells. It also includes the first report on the use of the cytokine interleukin-23 (IL-23) as a potential gene-delivered therapy against glioma.

"The pape
'"/>

Source:Cedars-Sinai Medical Center


Page: 1 2 3

Related biology news :

1. Wisconsin scientists grow critical nerve cells
2. Spleen may be source of versatile stem cells
3. Researchers discover way to make cells in the eye sensitive to light
4. Priming embryonic stem cells to fulfill their promise
5. Lack of enzyme turns fat cells into fat burners
6. Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas
7. Elusive HIV shape change revealed; Key clue to how virus infects cells
8. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
9. Enzyme allows B cells to resist death, leading to leukemia
10. Scientists rid stem cell culture of key animal cells
11. Genetically modified natural killer immune cells attack, kill leukemia cells
Post Your Comments:
(Date:7/2/2015)... , June 25, 2015 ... of the "Next Generation Biometrics Market by Application, ... report to their offering. The next ... by 2020, at a CAGR of 17.9% between 2015 ... leading application for the market. Safran SA ...
(Date:6/30/2015)... , June 30, 2015 To bolster its efforts ... HYPR Corp. announced today the addition of two new team ... as board advisor and David Raviv will act ... underscore HYPR Corp.,s commitment to providing the most secure solutions ... Sirota co-founded Layer 7 Technologies, a provider of security ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Latin America Biomedical Sensors Market Report 2015-2020 2
... bacteria of its ability to resist an antibiotic in ... health crisis. Rice environmental engineer Pedro Alvarez ... the Pseudomonas aeruginosa microorganism to resist the antibiotic medication ... Over 120 generations, the starving bacteria chose ...
... Bethesda, MD The Federation of American Societies for ... the Science Research Conference (SRC): Melatonin Biology: Actions & ... Biology: Actions & Therapeutics is an important and unique ... as a cytoprotective molecule and a physiological marker of ...
... behave differently. However, that difference isn,t taken into account ... children from chemical exposure, according to Cheryl Rosenfeld, associate ... Bond Life Sciences Center. A series of experiments by ... A (BPA) on later reproductive-associated behaviors using a socially ...
Cached Biology News:Lack of energy an enemy to antibiotic-resistant microbes 2Lack of energy an enemy to antibiotic-resistant microbes 3Bisphenol A affects sex-specific reproductive behaviors in a monogamous animal species 2
(Date:8/3/2015)... Medical, Inc. (Nasdaq: AEMD ), the pioneer in ... announced that it will host its First Quarter Fiscal ... 13, 2015 at 4:30 p.m. Eastern Time. ... fiscal 2016 first quarter results.  A recorded version of ... the call at the Investor Relations portion of the ...
(Date:8/3/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a ... autologous cell therapies, announced today that RepliCel,s CEO, David ... in Minneapolis, Minnesota on August 5 ... highlight RepliCel,s 18-month milestones including CE Mark for its RCI-02 ... clinical data from both RCT-01 (tendon) and RCS-01 (skin) clinical ...
(Date:7/31/2015)... KONG , July 31, 2015 China ... China,s leading provider of cord ... stem cell storage services, today announced that the Company ... the U.S. Securities and Exchange Commission. The filed Form ... ended March 31, 2015. The Form 20-F can be ...
(Date:7/30/2015)... , July 30, 2015   GenoSpace ... for the interpretation and analysis of genomic and ... Fischer has joined the company as Vice ... - http://photos.prnewswire.com/prnh/20150730/250931 "GenoSpace ... to integrate, interpret, analyze and explore complex sets ...
Breaking Biology Technology:Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2
... , ... Real-time in situ FTIR analysis has become a standard tool ... allows a more thorough understanding of reactions during the development and scale-up ... the Development of Batch and Continuous Chemical Processes Using Real-Time In Situ ...
... , ... Canadian Therapy Uses Energy Physics To Target Tissues Affected by Osteoarthritis. Physics and Biology ... ... announced today that its home-use medical device, the MyPhield Arthritis Therapy Cushion that naturally ...
... Nov. 3 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ... September 30, 2009. ISTA reported net revenue of $32.0 ... 47% increase over net revenue for the three months ended ... three months ended September 30, 2009 is $1.2 million associated ...
Cached Biology Technology:Development of Batch and Continuous Chemical Processes Using Real-Time In Situ FTIR Analytics as a Process Analytical Technology (PAT) Tool 2New Technology Now Available In Canada For Osteoarthritis 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 2ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 3ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 4ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 5ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 6ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 7ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 8ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results 9